Tesamorelin UK personal import rules

The short answer is that UK medicines law contains an explicit personal-import exemption, and that exemption is what most of the online argument about importing tesamorelin has never actually read. Regulation 17 of the Human Medicines Regulations 2012 requires a manufacturer's licence to import a medicinal product into Great Britain, then states that the requirement "does not apply to a person who imports a medicinal product for administration to himself or herself or to any other person who is a member of that person's household"^[2]. A personal import for your own use is not caught by that licensing rule. Selling it, supplying it, advertising it, or getting it past Border Force is a different question, and tesamorelin adds a wrinkle the other peptides do not have: it is an approved prescription medicine in the United States and an unauthorised one here.

This page describes the law and the enforcement pattern. It is not medical advice and it is not a green light. Tesamorelin has no UK marketing authorisation, the off-label uses it is usually bought for have no trial support, and any decision about whether to consider it belongs with a prescribing clinician who knows your history. The tesamorelin peptide page covers the evidence, and the UK regulation hub covers the wider picture, with the UK page for tesamorelin tracking the compound specifically. What follows is the import question.

Regulation 17(6): the personal-use carve-out

Regulation 17(1) is the licensing rule. It says a person may not import a medicinal product into Great Britain, from anywhere other than Northern Ireland or an approved country for import, without a manufacturer's licence^[2]. Regulation 17(6) then removes personal imports from that requirement. The wording turns on who the product is for, not on quantity, not on paperwork, and not on whether the product is licensed. If you import it to administer to yourself or to someone in your household, regulation 17(1) does not bite.

Compare that with the route a business has to take. The MHRA's guidance on importing a human medicine is written for wholesalers and manufacturers. It requires a wholesale distribution licence or a manufacturer's licence, and for an unlicensed medicine it requires the importer to notify the MHRA of the intent to import before the import happens, with the import only allowed to proceed if the MHRA does not object^[5]. There is no consumer version of that scheme, and the guidance says nothing about individuals importing for their own use. That silence is not a loophole. It is the reason regulation 17(6) has to exist as a separate carve-out.

What tesamorelin is under UK law

Tesamorelin is unusual in our library because it is a licensed medicine somewhere. In the United States it is approved as Egrifta and Egrifta SV, a growth-hormone-releasing factor analogue indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, prescription only, first approved in 2010^[7]. That approval is narrow, and it does not cross the Atlantic. A US prescription and a US label have no legal effect on what may be imported, sold or advertised in Great Britain.

In the UK there is no marketing authorisation for tesamorelin. The European application for Egrifta was withdrawn in June 2012 by the applicant, Ferrer Internacional, after the CHMP raised questions about the benefit-risk balance, and no sponsor has succeeded with a re-application since^[8]. Lawful access in the UK therefore runs only through the unlicensed-medicine, or named-patient, framework: a prescribing clinician requests an unlicensed import for a specific patient and takes responsibility for that prescription. General or online sale to the public is not one of the lawful routes. The regulation section of the tesamorelin page tracks the status across the jurisdictions we cover.

Worth saying plainly: the reason most UK buyers want tesamorelin has nothing to do with the approved indication. The interest is in body composition, recovery and anti-ageing, and the trial evidence for those uses is essentially absent. The published trials sit in the HIV-associated lipodystrophy population, on the labelled dose and endpoint. The what we do not yet know section goes through the gap in detail.

What stays illegal: selling, supplying, advertising

Regulation 46 is blunt: "A person may not sell or supply, or offer to sell or supply, an unauthorised medicinal product"^[3]. A product is unauthorised if no UK marketing authorisation, certificate of registration, traditional herbal registration or Article 126a authorisation is in force for it. No tesamorelin product holds any of those. So the vendor shipping to a UK address, the clinic offering an injection and the reseller splitting vials are all on the wrong side of regulation 46, even though the person receiving the vial for their own use is covered by regulation 17(6).

Advertising is caught separately. Regulation 279 prohibits publishing an advertisement in Great Britain for a medicinal product unless a marketing authorisation or an equivalent registration is in force for it^[4]. A UK listing that describes tesamorelin as reducing abdominal fat or raising growth hormone is advertising an unauthorised medicine, whatever the "research use only" line at the bottom of the page says.

That label trick fails on the definition itself. Regulation 2 defines a medicinal product two ways. The presentation limb catches "any substance or combination of substances presented as having properties of preventing or treating disease in human beings". The function limb catches any substance that may be administered to human beings "with a view to restoring, correcting or modifying a physiological function by exerting a pharmacological, immunological or metabolic action"^[1]. Stripping the health claims off a listing can defeat the presentation limb. It does nothing to the function limb, which is exactly what a growth-hormone-axis peptide is bought to do.

What customs actually flags

Regulation 17(6) exempts you from needing a manufacturer's licence. It does not oblige Border Force to wave a parcel through. The MHRA and Border Force run joint interception work at the UK border, most visibly through the recurring Operation Pangea. Operation Pangea XVIII ran from 10 to 23 March 2026 across roughly 90 countries and territories, and the agencies seized more than 2 million doses of illicit medicines with a stated value of £4.6 million^[6]. The MHRA's framing was that taking medicines obtained from unregulated sources can lead to serious harm.

For a personal parcel the realistic outcome is a seizure and a letter, not usually a prosecution. Enforcement effort concentrates on the supply side, because that is where regulations 46 and 279 give the MHRA something to prosecute, and postal interception is the cheap way to disrupt a vendor's business model. If a vial disappears between a customs shed and your door, the money is generally gone, because the transaction was not lawful at the seller's end and there is no consumer-protection route to recover it. Bulk quantities, repeat shipments to one address and packaging that looks like resale stock all invite a reading that has nothing to do with personal use.

The grey-market reality, without the endorsement

We do not recommend vendors for compounds that are unauthorised medicines, and tesamorelin is not going to be the exception. What we will do is state the supply picture plainly. The Egrifta and Egrifta SV products described on the US label are made by a manufacturer inside the regulated system, dispensed on prescription through licensed pharmacies^[7]. "Tesamorelin" from a research-chemical website is a different thing: no batch release, no pharmacopoeial identity testing, no adverse-event reporting route, and no assurance that the contents match the label.

So the import question turns out to be the least interesting part. A lawful personal import of an unlicensed product still leaves you holding a vial from a supplier operating outside medicines law, for an off-label purpose the trials never tested. The what we do not yet know section sets out how thin that evidence base actually is, and the same three regulations catch every unauthorised peptide sold to UK consumers. Only the handful with a UK authorisation, such as semaglutide, sit in a different position, which is why our UK regulation pages read almost identically compound to compound.

Where this lands

If you are a UK reader trying to work out your exposure: importing for your own use sits inside an express statutory exemption in regulation 17(6), selling or supplying or advertising to anyone else does not, and neither position makes the product authorised, safe or verified. The lawful way to be prescribed tesamorelin in the UK is through a clinician using the unlicensed-medicine route, not through a parcel.

This is educational, not legal or medical advice. If the distinction matters for a decision you are about to make, take it to a solicitor and to a clinician, because we are neither. Regulations and enforcement priorities change, so verify the current text of the Human Medicines Regulations 2012 on legislation.gov.uk and check the tesamorelin regulation section for the latest status before relying on any of the above.